MILLENDO THERAPEUTICS Email Format
Biotechnology ResearchMichigan, United States2-10 Employees
Millendo Therapeutics is a biotechnology company focused on developing treatments for endocrine diseases. It is advancing two product candidates: livoletide (AZP-531) for Prader-Willi syndrome and nevanimibe (ATR-101) for two orphan adrenal diseases—Classic Congenital Adrenal Hyperplasia and Endogenous Cushing's Syndrome. Based in Ann Arbor, Michigan, the company operates in the biotechnology research sector as a clinical-stage organization addressing unmet medical needs in endocrinology. In 2021, Millendo announced a merger with Tempest Therapeutics, a significant corporate development. The company maintains a small team.